{"id":533163,"date":"2021-03-08T14:44:01","date_gmt":"2021-03-08T14:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=533163"},"modified":"2021-03-08T14:44:01","modified_gmt":"2021-03-08T14:44:01","slug":"dysmenorrhea-market-size-share-trends-growth-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dysmenorrhea-market-size-share-trends-growth-leading-companies-emerging-drugs-and-epidemiology-forecast_533163.html","title":{"rendered":"Dysmenorrhea Market Size, Share, Trends, Growth, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dysmenorrhea Market Size, Share, Trends, Growth, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Dysmenorrhea Market Size, Share, Trends, Growth, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Dysmenorrhea Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">Painful menstrual periods in medical terms are described as <strong>Dysmenorrhea<\/strong>, which is often called &ldquo;menstrual cramps&rdquo; in simpler terms. Dysmenorrhea can be classified into two types: Primary Dysmenorrhea and Secondary Dysmenorrhea.<\/p>\n<p style=\"text-align: justify;\">The general cause behind menstrual cramps is the contractions (tightening) in the uterus by a chemical called prostaglandin. However, in secondary dysmenorrhea pain is caused by a disease in the woman&#8217;s reproductive organs such as endometriosis, adenomyosis, pelvic inflammatory disease, cervical stenosis, and fibroids. The <strong>Dysmenorrhea&nbsp;treatment<\/strong> pattern can be broadly divided into three parts: Pharmacological treatment, surgery, and Non- Pharmacological treatment.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at:&nbsp;<\/strong><br \/><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Dysmenorrhea market report<\/strong> also covers emerging drugs, current treatment practices, Dysmenorrhea market share of the individual therapies, current and forecasted Dysmenorrhea Market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Dysmenorrhea treatment practice<\/strong><strong>\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Dysmenorrhea Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/454e934d31a98dc8a7c94008e8ef6f94.jpg\" alt=\"Dysmenorrhea Market\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Dysmenorrhea Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the year 2017, the total <strong>prevalent case of Dysmenorrhea<\/strong> was 134,524,953 cases in the 7MM. The United States, in 2017, accounted for nearly 44% of the total 7MM cases.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU-5 countries, the highest number of cases of Dysmenorrhea were in Germany, i.e. 13,122,996 cases in the year 2017, which is estimated to rise by the year 2030.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2017, France accounted for 10,965,330 <strong>Dysmenorrhea cases<\/strong>&nbsp;in 2017, which are expected to rise by the year 2030.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the 7MM, Japan accounted for 18,442,399, and 2,410,771 <strong>Primary and Secondary Dysmenorrhea cases<\/strong>, respectively in 2017.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Key Benefits of Dysmenorrhea Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Dysmenorrhea market report<\/strong> provides an in-depth analysis of Dysmenorrhea Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Dysmenorrhea market report will help in developing business strategies by understanding the <strong>Dysmenorrhea Market trends &amp; developments<\/strong>, key players, and future market competition that will shape and drive the Dysmenorrhea market in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Dysmenorrhea market report covers <strong>Dysmenorrhea current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in 7 MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the <strong>Dysmenorrhea market<\/strong> in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population,&nbsp; comparative analysis of pipeline products with detailed clinical profiles, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dysmenorrhea-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Dysmenorrhea Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Dysmenorrhea market size<\/strong> is anticipated to increase during the forecast period owing to the increasing prevalence due to changing lifestyle, addiction to smoking and alcohol, expected increase in market penetration of current and as well emerging therapies, and increasing awareness about this disease.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Dysmenorrhea market outlook<\/strong> section of the report helps to build a detailed comprehension of the historic, current, and forecasted <strong>Dysmenorrhea market trends<\/strong> by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Dysmenorrhea market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dysmenorrhea Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Dysmenorrhea epidemiology<\/strong> section covers insights about the historical and current Dysmenorrhea patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dysmenorrhea Drugs Uptake and Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Dysmenorrhea Drugs<\/strong> Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dysmenorrhea market or expected to get launched in the market during the study period. The analysis covers Dysmenorrhea market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dysmenorrhea-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Dysmenorrhea market size<\/strong><\/a> is anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&amp;D activities.<\/p>\n<p style=\"text-align: justify;\"><strong>Dysmenorrhea Companies:<\/strong><br \/>Takeda<br \/>Mochida<br \/>AbbVie<br \/>ObsEva SA<br \/>Fuji Pharma&rsquo;s<br \/>Nobelpharma<br \/>Nippon Shinyaku<br \/>ASKA Pharmaceutical<br \/>Myovant Sciences GmbH<br \/>Pure Green Pharmaceuticals<br \/>Neurosciences Biosciences<br \/>And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>Dysmenorrhea Therapies covered in the report include:<\/strong><br \/>Pure Femme Tablets<br \/>FSN-013<br \/>Yselty<br \/>Relugolix<br \/>And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Dysmenorrhea Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Dysmenorrhea Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Dysmenorrhea Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Dysmenorrhea Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Dysmenorrhea Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Dysmenorrhea Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Dysmenorrhea Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Dysmenorrhea Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dysmenorrhea Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Dysmenorrhea Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Dysmenorrhea Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Dysmenorrhea Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dysmenorrhea Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Dysmenorrhea Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Dysmenorrhea Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Dysmenorrhea Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports &#8211;&nbsp;<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Dysmenorrhea Pipeline Insights<br \/><\/a><\/strong>Dysmenorrhea Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dysmenorrhea market.<\/p>\n<p style=\"text-align: justify;\"><strong>Other Latest Reports By Delveinsight &#8211;<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-a-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Hepatitis A Market Forecast<br \/><\/a><\/strong>DelveInsight&#8217; s &ldquo;Hepatitis A Market Insights, Epidemiology, and Market Forecast 2030&rdquo; report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Hepatitis A market size, share, trends, growth, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dysmenorrhea-market-size-share-trends-growth-leading-companies-emerging-drugs-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd. 2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dysmenorrhea-market-size-share-trends-growth-leading-companies-emerging-drugs-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Dysmenorrhea Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU5 (Germany, Spain, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dysmenorrhea-market-size-share-trends-growth-leading-companies-emerging-drugs-and-epidemiology-forecast_533163.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-533163","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=533163"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=533163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=533163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=533163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}